Randall C. Schatzman - 18 Feb 2022 Form 4 Insider Report for Bolt Biotherapeutics, Inc. (BOLT)

Role
Chief Executive Officer, Director
Signature
/s/ William P. Quinn, Attorney-in-Fact
Issuer symbol
BOLT
Transactions as of
18 Feb 2022
Net transactions value
$0
Form type
4
Filing time
23 Feb 2022, 20:18:08 UTC
Next filing
07 Feb 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BOLT Stock Option (Right to Buy) Award $0 +630,000 $0.000000 630,000 18 Feb 2022 Common Stock 630,000 $3.08 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the Shares will vest upon the Reporting Person completing each month of continuous service following January 1, 2022.